(Total Views: 345)
Posted On: 04/24/2021 5:37:39 AM
Post# of 36563
Even more knowing that IBRX aims at developing a vaccine with the same qualities and has much more funding opportunities.
My questions about GNBT would be:
- What about the joint entity in China? When should the trials start there?
- How much money is currently available for trials outside China? Should they refund Bintai according to this:
"If the Company fails to secure FDA approvals within 6 months of execution of the agreement, or a reasonable time thereafter, the advance must be returned to Bintai."
-Does the IND with the FDA includes china's trials?
Concerning NGIO spin-off, I don't know much about this, but if they need to raise 50M for NASDAQ compliance, who would spend such amount whereas they could buy all the GNBT shares for half of that?
Sorry if some questions are stupid but I am quite new here.
My questions about GNBT would be:
- What about the joint entity in China? When should the trials start there?
- How much money is currently available for trials outside China? Should they refund Bintai according to this:
"If the Company fails to secure FDA approvals within 6 months of execution of the agreement, or a reasonable time thereafter, the advance must be returned to Bintai."
-Does the IND with the FDA includes china's trials?
Concerning NGIO spin-off, I don't know much about this, but if they need to raise 50M for NASDAQ compliance, who would spend such amount whereas they could buy all the GNBT shares for half of that?
Sorry if some questions are stupid but I am quite new here.
(1)
(0)
